

Copyright Notice

CPT codes, descriptions and other data only are copyright 2024 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply. Fee schedules, relative value units, conversion factors and/or related components aren't assigned by the AMA, aren't part of CPT, and the AMA isn't recommending their use. The AMA doesn't directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Coverage & Billing Information for the 2025 Quarterly Code Update

Background

Iowa Medicaid has reviewed the **Q2 2025** Billing Code Update to determine coverage and billing guidelines. The Iowa Medicaid coverage and billing information provided in this bulletin is effective **April 1, 2025**. This bulletin serves as a notice of the following information:

Table 1

- New Current Procedural Terminology (CPT®) and Healthcare Common Procedure Coding System (HCPCS) codes included in the Q2 2025 code update. Coverage and billing information for these codes applies to dates of service on or after **April 1, 2025**.

Table 2

- New Current Dental Terminology (CDT®) codes included in the Q2 2025 code update. Coverage and billing information for these codes applies to dates of service on or after **N/A**.

Table 3

- International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. Coverage and billing for these codes applies to dates of service on or after **N/A**.

Table 4

- International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) codes. Coverage and billing for these codes applies to dates of service on or after **April 1, 2025**.

Table 5

- Modifiers included in the code update. Coverage and billing information for these codes applies to dates of service on or after **N/A**.

Table 6

- CPT®, CDT®, & HCPCS codes that would be considered Outpatient Hospital on or after **April 1, 2025**.

Table 7

- Non-Covered Codes - CPT®, CDT®, HCPCS, ICD-10-CM & ICD-10-PCS codes that have been thoroughly reviewed and Iowa Medicaid has decided not to cover effective **April 1, 2025**.

Table 8

- Deleted Codes - CPT®, CDT®, HCPCS, ICD-10-CM & ICD-10-PCS codes that have been discontinued effective **March 31, 2025**.

Managed Care Plans (MCPs) establish and publish reimbursement, prior authorization (PA), and billing information within the managed care delivery system. Questions about managed care PA should be directed to the MCP with which the member is enrolled.

Iowa Medicaid Provider Services:

- Phone: 1-800-338-7909
- Email: imeproviderservices@hhs.iowa.gov

Wellpoint Iowa, Inc.:

- Phone: 1-833-731-2143
- Email: ProviderSolutionsIA@wellpoint.com
- Website: <https://www.provider.wellpoint.com/iowa-provider/home>

Iowa Total Care:

- Phone: 1-833-404-1061
- Email: providerrelations@iowatotalcare.com
- Website: <https://www.iowatotalcare.com>

Molina Healthcare of Iowa:

- Phone: 1-844-236-1464
- Email: iaproviderrelations@molinahealthcare.com
- Website: <https://www.molinahealthcare.com/providers/ia/medicaid/home.aspx>
- Provider portal: <https://www.availity.com/molinahealthcare>

The **Q2 2025** code update may include modifications to descriptions for some existing HCPCS/CPT codes. These modifications are available for reference or download from the CMS website at www.cms.gov.

The **Q2** code update also includes a list of deleted codes. These codes are available for reference or download from the CMS website at cms.gov.

Iowa Medicaid will update the fee schedule as rates become available.

Table 1 – CPT® & HCPCS Codes

Code (Table 1)	Description	Effective Date
0945T	Intraoperative assessment for abnormal (tumor) tissue, in-vivo, following partial mastectomy (eg, lumpectomy) using computer-aided fluorescence imaging (List separately in addition to code for primary procedure)	4/1/2025
A9615	Injection, pegulicanine, 1 mg	4/1/2025
C9300	Injection, indigotindisulfonate sodium, 1 mg	4/1/2025
C9301	Obecabtagene autoleucel, up to 410 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	4/1/2025
C9302	Injection, zanidatamab-hrri, 2 mg	4/1/2025
C9303	Injection, zolbetuximab-clzb, 1 mg	4/1/2025
C9304	Injection, marstacimab-hncq, 0.5 mg	4/1/2025
J0281	Injection, aminocaproic acid, 1 gram	4/1/2025
J1072	Injection, testosterone cypionate (azmiro), 1 mg	4/1/2025
J1271	Injection, doxycycline hyclate, 1 mg	4/1/2025
J1299	Injection, eculizumab, 2 mg	4/1/2025
J1308	Injection, famotidine, 0.25 mg	4/1/2025
J1808	Injection, folic acid, 0.1 mg	4/1/2025
J1938	Injection, furosemide, 1 mg	4/1/2025
J2351	Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq	4/1/2025
J2428	Injection, paliperidone palmitate extended release (erzofri), 1 mg	4/1/2025
J2804	Injection, rifampin, 1 mg	4/1/2025
J2865	Injection, sulfamethoxazole 5 mg and trimethoprim 1 mg	4/1/2025
J7521	Tacrolimus, granules, oral suspension, 0.1 mg	4/1/2025
J9024	Injection, atezolizumab, 5 mg and hyaluronidase-tqjs	4/1/2025
J9038	Injection, axatilimab-csfr, 0.1 mg	4/1/2025
J9054	Injection, bortezomib (boruzu), 0.1 mg	4/1/2025
Q2057	Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose	4/1/2025

Code (Table 1)	Description	Effective Date
Q5147	Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg	4/1/2025
Q5149	Injection, aflibercept-abzv (enzeevu), biosimilar, 1 mg	4/1/2025
Q5152	Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg	4/1/2025
Q9999	Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg	4/1/2025

Table 2 – CDT©

Code (Table 2)	Description	Effective Date
N/A		

Table 3 – ICD-10-CM Codes

Code (Table 3)	Description	Effective Date
N/A		

Table 4 – ICD-10-PCS Codes

Code (Table 4)	Description	Effective Date
0B118D6	Bypass Trachea to Esophagus with Intraluminal Device, Via Natural or Artificial Opening Endoscopic	4/1/2025
0CYS0Z0	Transplantation of Larynx, Allogeneic, Open Approach	4/1/2025
0CYS0Z1	Transplantation of Larynx, Syngeneic, Open Approach	4/1/2025
0DX80Z7	Transfer Small Intestine to Vagina, Open Approach	4/1/2025
0DX84Z7	Transfer Small Intestine to Vagina, Percutaneous Endoscopic Approach	4/1/2025
0TT00Z0	Resection of Right Kidney, Open Approach, Allogeneic	4/1/2025
0TT00Z1	Resection of Right Kidney, Open Approach, Syngeneic	4/1/2025
0TT00Z2	Resection of Right Kidney, Open Approach, Zooplastic	4/1/2025
0TT10Z0	Resection of Left Kidney, Open Approach, Allogeneic	4/1/2025
0TT10Z1	Resection of Left Kidney, Open Approach, Syngeneic	4/1/2025

Code (Table 4)	Description	Effective Date
0TT10ZZ	Resection of Left Kidney, Open Approach, Zooplastic	4/1/2025
0U7C7DJ	Dilation of Cervix with Intraluminal Device, Temporary, Via Natural or Artificial Opening	4/1/2025
10D10ZZ	Extraction of Products of Conception, Retained, Open Approach	4/1/2025
3E0U0GC	Introduction of Other Therapeutic Substance into Joints, Open Approach	4/1/2025
D228DZZ	Stereotactic Other Photon Radiosurgery of Conduction Mechanism	4/1/2025
X2KA30A	Bypass Left Atrium using Conduit through Coronary Sinus to Right Atrium, Percutaneous Approach, New Technology Group 10	4/1/2025
X2U93YA	Supplement Right Atrium with Intraluminal Device, Heterotopic Bioprosthetic Valve(s), Percutaneous Approach, New Technology Group 10	4/1/2025
XNS40GA	Reposition Right Humeral Shaft with Ring External Fixation Device with Automated Strut Adjustment, Open Approach, New Technology Group 10	4/1/2025
XNS43GA	Reposition Right Humeral Shaft with Ring External Fixation Device with Automated Strut Adjustment, Percutaneous Approach, New Technology Group 10	4/1/2025
XNS50GA	Reposition Left Humeral Shaft with Ring External Fixation Device with Automated Strut Adjustment, Open Approach, New Technology Group 10	4/1/2025
XNS53GA	Reposition Left Humeral Shaft with Ring External Fixation Device with Automated Strut Adjustment, Percutaneous Approach, New Technology Group 10	4/1/2025
XNS60GA	Reposition Right Radius with Ring External Fixation Device with Automated Strut Adjustment, Open Approach, New Technology Group 10	4/1/2025
XNS63GA	Reposition Right Radius with Ring External Fixation Device with Automated Strut Adjustment, Percutaneous Approach, New Technology Group 10	4/1/2025
XNS70GA	Reposition Left Radius with Ring External Fixation Device with Automated Strut Adjustment, Open Approach, New Technology Group 10	4/1/2025
XNS73GA	Reposition Left Radius with Ring External Fixation Device with Automated Strut Adjustment, Percutaneous Approach, New Technology Group 10	4/1/2025
XNS80GA	Reposition Right Ulna with Ring External Fixation Device with Automated Strut Adjustment, Open Approach, New Technology Group 10	4/1/2025
XNS83GA	Reposition Right Ulna with Ring External Fixation Device with Automated Strut Adjustment, Percutaneous Approach, New Technology Group 10	4/1/2025

Code (Table 4)	Description	Effective Date
XNS90GA	Reposition Left Ulna with Ring External Fixation Device with Automated Strut Adjustment, Open Approach, New Technology Group 10	4/1/2025
XNS93GA	Reposition Left Ulna with Ring External Fixation Device with Automated Strut Adjustment, Percutaneous Approach, New Technology Group 10	4/1/2025
XNSA0GA	Reposition Right Upper Femur with Ring External Fixation Device with Automated Strut Adjustment, Open Approach, New Technology Group 10	4/1/2025
XNSA3GA	Reposition Right Upper Femur with Ring External Fixation Device with Automated Strut Adjustment, Percutaneous Approach, New Technology Group 10	4/1/2025
XNSB0GA	Reposition Left Upper Femur with Ring External Fixation Device with Automated Strut Adjustment, Open Approach, New Technology Group 10	4/1/2025
XNSB3GA	Reposition Left Upper Femur with Ring External Fixation Device with Automated Strut Adjustment, Percutaneous Approach, New Technology Group 10	4/1/2025
XNSC0GA	Reposition Right Lower Femur with Ring External Fixation Device with Automated Strut Adjustment, Open Approach, New Technology Group 10	4/1/2025
XNSC3GA	Reposition Right Lower Femur with Ring External Fixation Device with Automated Strut Adjustment, Percutaneous Approach, New Technology Group 10	4/1/2025
XNSD0GA	Reposition Left Lower Femur with Ring External Fixation Device with Automated Strut Adjustment, Open Approach, New Technology Group 10	4/1/2025
XNSD3GA	Reposition Left Lower Femur with Ring External Fixation Device with Automated Strut Adjustment, Percutaneous Approach, New Technology Group 10	4/1/2025
XNSE0GA	Reposition Right Femoral Shaft with Ring External Fixation Device with Automated Strut Adjustment, Open Approach, New Technology Group 10	4/1/2025
XNSE3GA	Reposition Right Femoral Shaft with Ring External Fixation Device with Automated Strut Adjustment, Percutaneous Approach, New Technology Group 10	4/1/2025
XNSF0GA	Reposition Left Femoral Shaft with Ring External Fixation Device with Automated Strut Adjustment, Open Approach, New Technology Group 10	4/1/2025
XNSF3GA	Reposition Left Femoral Shaft with Ring External Fixation Device with Automated Strut Adjustment, Percutaneous Approach, New Technology Group 10	4/1/2025
XNSG0GA	Reposition Right Tibia with Ring External Fixation Device with Automated Strut Adjustment, Open Approach, New Technology Group 10	4/1/2025

Code (Table 4)	Description	Effective Date
XNSG3GA	Reposition Right Tibia with Ring External Fixation Device with Automated Strut Adjustment, Percutaneous Approach, New Technology Group 10	4/1/2025
XNSH0GA	Reposition Left Tibia with Ring External Fixation Device with Automated Strut Adjustment, Open Approach, New Technology Group 10	4/1/2025
XNSH3GA	Reposition Left Tibia with Ring External Fixation Device with Automated Strut Adjustment, Percutaneous Approach, New Technology Group 10	4/1/2025
XW033MA	Introduction of Emapalumab-Izsg Anti-IFN γ Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 10	4/1/2025
XW033NA	Introduction of Tarlatamab-dlle Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10	4/1/2025
XW043MA	Introduction of Emapalumab-Izsg Anti-IFN γ Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 10	4/1/2025
XW043NA	Introduction of Tarlatamab-dlle Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10	4/1/2025
XXE5X5A	Measurement of Immune Response, Whole Blood Cellular Assessment via Microfluidic Deformability, New Technology Group 10	4/1/2025

Table 5 - Modifiers

Code (Table 5)	Description	Effective Date
N/A		

Table 6 – Outpatient Hospital

Code (Table 6)	Description	Effective Date
0945T	Intraoperative assessment for abnormal (tumor) tissue, in-vivo, following partial mastectomy (eg, lumpectomy) using computer-aided fluorescence imaging (List separately in addition to code for primary procedure)	4/1/2025
A9615	Injection, pegulicanine, 1 mg	4/1/2025
C9300	Injection, indigotindisulfonate sodium, 1 mg	4/1/2025

Code (Table 6)	Description	Effective Date
C9301	Obecabtagene autoleucel, up to 410 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	4/1/2025
C9302	Injection, zanidatamab-hrii, 2 mg	4/1/2025
C9303	Injection, zolbetuximab-clzb, 1 mg	4/1/2025
C9304	Injection, marstacimab-hncq, 0.5 mg	4/1/2025
J0281	Injection, aminocaproic acid, 1 gram	4/1/2025
J1072	Injection, testosterone cypionate (azmiro), 1 mg	4/1/2025
J1271	Injection, doxycycline hyclate, 1 mg	4/1/2025
J1299	Injection, eculizumab, 2 mg	4/1/2025
J1308	Injection, famotidine, 0.25 mg	4/1/2025
J1808	Injection, folic acid, 0.1 mg	4/1/2025
J1938	Injection, furosemide, 1 mg	4/1/2025
J2351	Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq	4/1/2025
J2428	Injection, paliperidone palmitate extended release (erzofri), 1 mg	4/1/2025
J2804	Injection, rifampin, 1 mg	4/1/2025
J2865	Injection, sulfamethoxazole 5 mg and trimethoprim 1 mg	4/1/2025
J7521	Tacrolimus, granules, oral suspension, 0.1 mg	4/1/2025
J9024	Injection, atezolizumab, 5 mg and hyaluronidase-tqjs	4/1/2025
J9038	Injection, axatilimab-csfr, 0.1 mg	4/1/2025
J9054	Injection, bortezomib (boruzu), 0.1 mg	4/1/2025
Q2057	Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose	4/1/2025
Q5147	Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg	4/1/2025
Q5149	Injection, aflibercept-abzv (enzeevu), biosimilar, 1 mg	4/1/2025
Q5152	Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg	4/1/2025
Q9999	Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg	4/1/2025

Table 7 – Noncovered Codes

Code (Table 7)	Description	Effective Date
0531U	DNA next-generation sequencing of 673 infectious disease organisms	4/1/2025
0532U	Rapid whole genome and mitochondrial DNA sequencing for rare diseases	4/1/2025
0533U	Genotyping of 16 genes reported as metabolizer status and transporter function for drug metabolism	4/1/2025
0534U	MicroRNA, single-nucleotide polymorphisms (SNPs) analysis of 32 variants reported as a risk score for prostate cancer	4/1/2025
0535U	Testing for perfluoroalkyl substances (PFAS)	4/1/2025
0536U	Red blood cell antigen (fetal RhD) testing in pregnant individuals known to be RhD negative, reported as fetal RhD status	4/1/2025
0537U	DNA next-generation sequencing of more than 2500 differentiated methylated regions (DMRs), reported as positive or negative in colorectal cancer	4/1/2025
0538U	DNA next generation sequencing of 600 genes, reported as actionable variant in solid tumor cancers	4/1/2025
0539U	DNA next-generation sequencing of 152 genes reported as actionable variant in solid tumor cancers	4/1/2025
0540U	DNA next-generation sequencing reported as a percentage of donor-derived cell-free DNA to determine probability of transplant rejection	4/1/2025
0541U	Testing for 5 HAD-bound apolipoproteins reported as prediction of coronary artery disease (pCAD) score	4/1/2025
0542U	Nuclear magnetic resonance (NMR) spectroscopy measurement of 84 urinary metabolites reported as probability score for allograft injury status in renal transplant	4/1/2025
0543U	DNA next-generation sequencing of 517 genes in solid tumor cancers	4/1/2025
0544U	Testing of 48 variants reported as risk for transplant rejection	4/1/2025
0545U	Testing for acetylcholine receptor (AChR) antibodies, reported as positive or negative	4/1/2025
0546U	Testing for low-density lipoprotein receptor-related protein 4 (LRP4) antibodies, reported as positive or negative	4/1/2025
0547U	Testing for neurofilament light chain (NfL)	4/1/2025

Code (Table 7)	Description	Effective Date
0548U	Testing for glial fibrillary acidic protein (GFAP)	4/1/2025
0549U	DNA testing for biomarkers reported as probability index for bladder cancer and/or upper tract urothelial carcinoma (UTUC)	4/1/2025
0550U	Testing for prostate-specific antigen, reported as a risk score for the presence of high-grade prostate cancer	4/1/2025
0551U	Testing for phosphorylated Tau (pTau217)	4/1/2025
A2030	Miro3d fibers, per milligram	4/1/2025
A2031	Mirodry wound matrix, per square centimeter	4/1/2025
A2032	Myriad matrix, per square centimeter	4/1/2025
A2033	Myriad morcells, 4 milligrams	4/1/2025
A2034	Foundation drs solo, per square centimeter	4/1/2025
A2035	Corplex p or theracor p or allacor p, per milligram	4/1/2025
A6515	Gradient compression wrap with adjustable straps, full leg, each, custom	4/1/2025
A6516	Gradient compression wrap with adjustable straps, foot, each, custom	4/1/2025
A6517	Gradient compression wrap with adjustable straps, below knee, each, custom	4/1/2025
A6518	Gradient compression wrap with adjustable straps, arm, each, custom	4/1/2025
A6519	Gradient compression garment, not otherwise specified, for nighttime use, each	4/1/2025
A6611	Gradient compression wrap with adjustable straps, above knee, each, custom	4/1/2025
A9154	Artificial saliva, 1 ml	4/1/2025
A9611	Flurpiridaz f 18, diagnostic, 1 millicurie	4/1/2025
C8004	Simulation angiogram with use of a pressure-generating cath, inclusive of all radiological S & I, intraprocedural roadmapping, & imaging guidance necessary to complete the angiogram, for subsequent radioembolization of tumors	4/1/2025
C8005	Bronchoscopy, rigid or flexible, non-thermal transbronchial ablation of lesion(s) by pulsed electric field energy	4/1/2025
E0201	Penile contracture device, manual, greater than 3 lbs traction force	4/1/2025
E1022	Wheelchair transportation securement system, any type includes all components and accessories	4/1/2025
E1023	Wheelchair transit securement system, includes all components and accessories	4/1/2025

Code (Table 7)	Description	Effective Date
E1032	Wheelchair accessory, manual swingaway, retractable or removable mounting hardware used with joystick or other drive control interface	4/1/2025
E1033	Wheelchair accessory, manual swingaway, retractable or removable mounting hardware for headrest, cushioned, any type	4/1/2025
E1034	Wheelchair accessory, manual swingaway, retractable or removable mounting hardware for lateral trunk or hip support, any type	4/1/2025
E1832	Static progressive stretch finger device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories	4/1/2025
G0183	Quantitative software measurements of cardiac volume, cardiac chambers volumes and left ventricular wall mass derived from ct scan(s) data of the chest/heart (with or without contrast)	4/1/2025
G0566	3d radiodensity-value bone imaging, algorithm derived, from previous magnetic resonance examination of the same anatomy	4/1/2025
G0567	Infectious agent detection by nucleic acid (dna or rna); hepatitis c, screening, amplified probe technique	4/1/2025
J9161	Injection, denileukin diftiox-cxdl, 1 mcg	4/1/2025
L0720	Cervical-thoracic-lumbar-sacral-orthoses (ctlso), anterior-posterior-lateral control, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise	4/1/2025
L1933	Ankle foot orthosis, rigid anterior tibial section, total carbon fiber or equal material, prefabricated, off-the-shelf	4/1/2025
L1952	Ankle foot orthosis, spiral, (institute of rehabilitative medicine type), plastic or other material, prefabricated, off-the-shelf	4/1/2025
L5827	Endoskeletal knee-shin system, single axis, electromechanical swing and stance phase control, with or without shock absorption and stance extension damping	4/1/2025
L6028	Partial hand including fingers, flexible or non-flexible interface, endoskeletal system, molded to patient model, for use without external power, not including inserts described by L6692	4/1/2025
L6029	Upper extremity addition, test socket/interface, partial hand including fingers	4/1/2025
L6030	Upper extremity addition, external frame, partial hand including fingers	4/1/2025

Code (Table 7)	Description	Effective Date
L6031	Replacement socket/interface, partial hand including fingers, molded to patient model, for use with or without external power	4/1/2025
L6032	Addition to upper extremity prosthesis, partial hand including fingers, ultralight material (titanium, carbon fiber or equal)	4/1/2025
L6033	Addition to upper extremity prosthesis, partial hand including fingers, acrylic material	4/1/2025
L6037	Immediate post-surgical or early fitting, application of initial rigid dressing, including fitting alignment and suspension of components, and one cast change, partial hand including fingers	4/1/2025
L6700	Upper extremity addition, external powered feature, myoelectronic control module, additional emg inputs, pattern-recognition decoding intent movement	4/1/2025
L7406	Addition to upper extremity, user adjustable, mechanical, residual limb volume management system	4/1/2025
Q4354	Palingen dual-layer membrane, per square centimeter	4/1/2025
Q4355	Abiomend xplus membrane and abiomend xplus hydromembrane, per square centimeter	4/1/2025
Q4356	Abiomend membrane and abiomend hydromembrane, per square centimeter	4/1/2025
Q4357	Xwrap plus, per square centimeter	4/1/2025
Q4358	Xwrap dual, per square centimeter	4/1/2025
Q4359	Choriplay, per square centimeter	4/1/2025
Q4360	Amchoplast fd, per square centimeter	4/1/2025
Q4361	Epixpress, per square centimeter	4/1/2025
Q4362	Cygnus disk, per square centimeter	4/1/2025
Q4363	Amnio burgeon membrane and hydromembrane, per square centimeter	4/1/2025
Q4364	Amnio burgeon xplus membrane and xplus hydromembrane, per square centimeter	4/1/2025
Q4365	Amnio burgeon dual-layer membrane, per square centimeter	4/1/2025
Q4366	Dual layer amnio burgeon x-membrane, per square centimeter	4/1/2025
Q4367	Amniocore sl, per square centimeter	4/1/2025
Q5148	Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram	4/1/2025

Code (Table 7)	Description	Effective Date
Q5150	Injection, aflibercept-mrbb (ahzantive), biosimilar, 1 mg	4/1/2025
Q5151	Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg	4/1/2025
S4024	Air polymer-type a intrauterine foam, per study dose	4/1/2025

Table 8 – Deleted Codes

Code (Table 8)	Description	Effective Date
0SG604Z	Fusion of Coccygeal Joint with Internal Fixation Device, Open Approach	3/31/2025
0SG604Z	Fusion of Coccygeal Joint with Internal Fixation Device, Open Approach	3/31/2025
0SG607Z	Fusion of Coccygeal Joint with Autologous Tissue Substitute, Open Approach	3/31/2025
0SG607Z	Fusion of Coccygeal Joint with Autologous Tissue Substitute, Open Approach	3/31/2025
0SG60JZ	Fusion of Coccygeal Joint with Synthetic Substitute, Open Approach	3/31/2025
0SG60JZ	Fusion of Coccygeal Joint with Synthetic Substitute, Open Approach	3/31/2025
0SG60KZ	Fusion of Coccygeal Joint with Nonautologous Tissue Substitute, Open Approach	3/31/2025
0SG60KZ	Fusion of Coccygeal Joint with Nonautologous Tissue Substitute, Open Approach	3/31/2025
0SG634Z	Fusion of Coccygeal Joint with Internal Fixation Device, Percutaneous Approach	3/31/2025
0SG637Z	Fusion of Coccygeal Joint with Autologous Tissue Substitute, Percutaneous Approach	3/31/2025
0SG63JZ	Fusion of Coccygeal Joint with Synthetic Substitute, Percutaneous Approach	3/31/2025
0SG63KZ	Fusion of Coccygeal Joint with Nonautologous Tissue Substitute, Percutaneous Approach	3/31/2025
0SG644Z	Fusion of Coccygeal Joint with Internal Fixation Device, Percutaneous Endoscopic Approach	3/31/2025
0SG647Z	Fusion of Coccygeal Joint with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	3/31/2025
0SG64JZ	Fusion of Coccygeal Joint with Synthetic Substitute, Percutaneous Endoscopic Approach	3/31/2025
0SG64KZ	Fusion of Coccygeal Joint with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	3/31/2025

Code (Table 8)	Description	Effective Date
A9155	Artificial saliva, 30 ml	3/31/2025
J1094	Injection, dexamethasone acetate, 1 mg	3/31/2025
J1300	Injection, eculizumab, 10 mg	3/31/2025
J1810	Injection, droperidol and fentanyl citrate, up to 2 ml ampule	3/31/2025
J1890	Injection, cephalothin sodium, up to 1 gram	3/31/2025
J1940	Injection, furosemide, up to 20 mg	3/31/2025
J9037	Injection, belantamab mafodotin-blmf, 0.5 mg	3/31/2025
J9247	Injection, melphalan flufenamide, 1mg	3/31/2025
L8010	Breast prosthesis, mastectomy sleeve	3/31/2025
Q4231	Corplex p, per cc	3/31/2025
S0017	Injection, aminocaproic acid, 5 grams	3/31/2025
S0028	Injection, famotidine, 20 mg	3/31/2025
S0032	Injection, nafcillin sodium, 2 grams	3/31/2025
S0039	Injection, sulfamethoxazole and trimethoprim, 10 ml	3/31/2025
S4988	Penile contracture device, manual, greater than 3 lbs traction force	3/31/2025